Vandetanib plus pernetrexed versus pemetrexed as 2nd-line therapy in patients with advanced NSCLC: a randomized, double-blind phase III trial (ZEAL)

被引：0
|
作者：
de Boer, Richard H. [1 ]
Arrieta, Oscar [2 ]
Gottfried, Maya [3 ]
Blackhall, Fiona H. [4 ]
Raats, Johann [5 ]
Yang, Chih-Hsin [6 ]
Langmuir, Peter [7 ]
Milenkova, Tsveta [8 ]
Read, Jessica [8 ]
Vansteenkiste, Johan [9 ]
机构：
[1] Western Hosp, Melbourne, Vic, Australia
[2] Inst Nacl Cancerol, Mexico City, DF, Mexico
[3] Meir Med Ctr, Kefar Sava, Israel
[4] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England
[5] Panorama Med Ctr, Cape Town, South Africa
[6] Natl Taiwan Univ Hosp, Taipei, Taiwan
[7] AstraZeneca, Wilmington, DE USA
[8] AstraZeneca, Macclesfield, Cheshire, England
[9] Katholieke Univ Leuven Hosp, Leuven, Belgium
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S356 / S357
页数：2
相关论文
共 50 条
  • [21] Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
    Finn, Richard S.
    Ryoo, Baek-Yeol
    Merle, Philippe
    Kudo, Masatoshi
    Bouattour, Mohamed
    Lim, Ho Yeong
    Breder, Valeriy
    Edeline, Julien
    Chao, Yee
    Ogasawara, Sadahisa
    Yau, Thomas
    Garrido, Marcelo
    Chan, Stephen L.
    Knox, Jennifer
    Daniele, Bruno
    Ebbinghaus, Scot W.
    Chen, Erluo
    Siegel, Abby B.
    Zhu, Andrew X.
    Cheng, Ann-Lii
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (03) : 193 - +
  • [22] Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial (vol 30, pg 134, 2012)
    Wells, S. A., Jr.
    Robinson, B. G.
    Gagel, R. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (24) : 3049 - 3049
  • [23] Camrelizumab or placebo plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-sq): A randomized, double-blind, multicenter, phase III trial
    Zhou, C.
    Ren, S.
    Chen, J.
    Xu, X.
    Cheng, Y.
    Chen, G.
    Pan, Y.
    Fang, Y.
    Wang, Q.
    Huang, Y.
    Yao, W.
    Wang, R.
    Li, X.
    Zhang, W.
    Zhang, Y.
    Hu, S.
    Guo, R.
    Yang, Z.
    Wang, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S748 - S748
  • [24] Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial
    Middleton, Gary
    Palmer, Daniel H.
    Greenhalf, William
    Ghaneh, Paula
    Jackson, Richard
    Cox, Trevor
    Evans, Anthony
    Shaw, Victoria E.
    Wadsley, Jonathan
    Valle, Juan W.
    Propper, David
    Wasan, Harpreet
    Falk, Stephen
    Cunningham, David
    Coxon, Fareeda
    Ross, Paul
    Madhusudan, Srinivasan
    Wadd, Nick
    Corrie, Pippa
    Hickish, Tamas
    Costello, Eithne
    Campbell, Fiona
    Rawcliffe, Charlotte
    Neoptolemos, John P.
    [J]. LANCET ONCOLOGY, 2017, 18 (04): : 486 - 499
  • [25] Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial
    Cheng, Y.
    Yang, R.
    Chen, J.
    Zhang, W.
    Xie, C.
    Hu, Q.
    Zhou, N.
    Huang, C.
    Wei, S.
    Sun, H.
    Li, X.
    Yu, Y.
    Lai, J.
    Yang, H.
    Fang, H.
    Chen, H.
    Zhang, P.
    Gu, K.
    Wang, Q.
    Shi, J.
    Yi, T.
    Xu, X.
    Ye, X.
    Wang, D.
    Xie, C.
    Liu, C.
    Zheng, Y.
    Lin, D.
    Zhuang, W.
    Lu, P.
    Yu, G.
    Li, J.
    Gu, Y.
    Li, B.
    Wu, R.
    Jiang, O.
    Wang, Z.
    Wu, G.
    Lin, H.
    Zhong, D.
    Xu, Y.
    Shu, Y.
    Wu, D.
    Chen, X.
    Wang, J.
    Wang, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S44 - S44
  • [26] Results of a randomized, double-blind Phase II trial of ZD6474 versus gefitinib in patients with NSCLC
    Ranson, M.
    Bodkin, D.
    Govindan, R.
    Sleckman, B.
    Rizvi, N.
    Capo, A.
    Germonpre, R.
    Dimery, I.
    Webster, A.
    Natale, R.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 324 - 325
  • [27] Pemetrexed plus gemcitabine versus gemcitabine plus carboplatin in patients with advanced nanoperable NSCLC: A randomized phase II study
    Hillerdal, G. N.
    Koyi, H.
    Branden, E.
    Kolbeck, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer
    Choueiri, Toni K.
    Ross, Robert W.
    Jacobus, Susanna
    Vaishampayan, Ulka
    Yu, Evan Y.
    Quinn, David I.
    Hahn, Noah M.
    Hutson, Thomas E.
    Sonpavde, Guru
    Morrissey, Stephanie C.
    Buckle, Geoffrey C.
    Kim, William Y.
    Petrylak, Daniel P.
    Ryan, Christopher W.
    Eisenberger, Mario A.
    Mortazavi, Amir
    Bubley, Glenn J.
    Taplin, Mary-Ellen
    Rosenberg, Jonathan E.
    Kantoff, Philip W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05) : 507 - 512
  • [29] SEARCH: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patients With Advanced Hepatocellular Carcinoma
    Zhu, Andrew X.
    Rosmorduc, Olivier
    Evans, T. R. Jeffry
    Ross, Paul J.
    Santoro, Armando
    Carrilho, Flair Jose
    Bruix, Jordi
    Qin, Shukui
    Thuluvath, Paul J.
    Llovet, Josep M.
    Leberre, Marie-Aude
    Jensen, Markus
    Meinhardt, Gerold
    Kang, Yoon-Koo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (06) : 559 - 566
  • [30] Randomized, double-blind, and multicenter phase II trial of rh-endostatin plus dacarbazine versus dacarbazine alone as first-line therapy for the patients with advanced melanoma.
    Guo, Jun
    Cui, Chuan Liang
    Gu, Kangsheng
    Tao, Min
    Xin, Song
    Lin, Tongyu
    Ren, Xiu Bao
    Qin, Shukui
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345